DelMar Pharmaceuticals (NSDQ:DMPI) said today that the FDA granted its lead product candidate, VAL-083, fast track status for approval as a therapy for recurrent glioblastoma.
The designation applies to a Phase II trial with the University of Texas MD Anderson Cancer Center and a Phase III trial in patients whose disease has progressed after treatment with temozolomide and bevacizumab.
Get the full story at our sister site, Drug Delivery Business News.
The post DelMar Pharma wins fast track status for glioblastoma drug appeared first on MassDevice.